Intercept hits regulatory snag at FDA, likely delaying NASH drug’s approval

Intercept hits regulatory snag at FDA, likely delaying NASH drug’s approval

The company said that the agency had requested additional data for obeticholic acid and thus moved the upcoming advisory committee meeting from June 9 to June 26, thereby delaying its decision on approval, which had also been scheduled for June 26.

Source: https://ift.tt/2Xk6H3N